Here's some thoughts on possible valuation of LXXGF.
If 5% of the 70,000 vets buys an LX2 that's 3500 vets. Times 1000 tests a year per vet that's 3.5M tests. Times $96 a test is $336M in cartridge sales. Add 3500 LX2's at $40k each is $140M sales. $336M + $140M = $476M revenue.
A conservative valuation would be 4x sales = $1.9B divided by say 120M shares out = $16/sh.
Now add into the mix sales of unit and testing for water, air, food, agriculture, humans just in the USA and that number could grow by 5X That puts valuation at nearly $10B + 120M shares = $83/sh.
Cut those numbers in half and it's still pretty interesting.
